Latest news with #AbTherx
Associated Press
16-06-2025
- Business
- Associated Press
AbTherx and GPCR Therapeutics Announce a Strategic Collaboration to Discover Novel Antibody-based Therapeutics for GPCR Targets
Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / ACCESS Newswire / June 16, 2025 / AbTherx, a biotechnology company with innovative technologies that enable therapeutic antibody discovery against challenging targets, today announced a research collaboration with GPCR Therapeutics, a clinical-stage biopharmaceutical company, to discover and develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for one target, with the potential to expand to additional targets. AbTherx's antibody discovery platform is built on two decades of experience and utilizes the immune system's evolutionary intelligence to identify diverse and developable human antibodies. This collaboration leverages AbTherx's innovative, patent-pending Atlas Long CDR3 Mouse to create antibodies with long CDR3 regions, providing the unique opportunity to access buried epitopes within GPCRs, ion channels, and other difficult targets. These fully human antibodies minimize developability and immunogenicity risk by leveraging a rare, naturally occurring phenomenon in humans. GPCR Therapeutics is developing drugs targeting GPCRs to treat cancer, fibrosis, and obesity. Its stem cell mobilization program is now undergoing a phase 2 clinical trial in the United States of America. The company has also established capabilities for antigen development, antibody screening, and profiling for the discovery of antibodies targeting GPCRs, which are historically known to be challenging targets for antibody discovery. 'We are excited to strategically partner with GPCR Therapeutics to co-create a potentially life-saving therapeutic, leveraging the full power of the AbTherx team, combining a potentially best-in-class antibody discovery platform with a highly successful team of drug hunters,' said Justin Mika, CEO of AbTherx. 'This collaboration is a first for our proprietary Atlas Long CDR3 Mouse. We are keen to explore the full potential of this technology to discover and develop transformative, new antibody therapies for challenging targets.' 'We are thrilled to collaborate with one of the world's most experienced antibody discovery teams,' said Dong Seung Seen, CEO of GPCR Therapeutics. 'Our partnership with AbTherx marks a significant milestone for GPCR Therapeutics, strategically enhancing our ability to generate therapeutic antibodies against our priority targets. By combining our respective strengths, we aim to explore the largely uncharted territory of GPCR-targeting antibodies, ultimately striving to bring multiple first-in-class therapies to patients. The potential to expand our focus to additional targets in oncology, fibrosis, and obesity, further underscores the strategic value of this collaboration.' AbTherx has a range of partnering strategies from technology licensing to strategic collaborations. The Long CDR3 technology has the potential to deliver high-impact therapeutics for some of the most challenging targets. It is available for strategic research collaborations and co-development partnerships aimed at advancing innovative therapeutics. This AbTherx and GPCR Therapeutics partnership is expected to yield a pre-clinical asset governed by a 50/50 ownership structure, drawing on the complementary strengths and resources of both parties to develop a novel modality targeting GPCRs, the largest and most diverse family of drug targets. About AbTherx AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit About GPCR Therapeutics GPCR Therapeutics, Inc. is a clinical-stage biopharmaceutical company taking an innovative approach to developing therapeutics based on its proprietary GPCR science. The company is currently conducting a Phase 2 clinical trial in the U.S. to evaluate the efficacy of GPC-100 in combination with propranolol in patients with multiple myeloma, in collaboration with Exicure. In addition to its lead program, GPCR Therapeutics is advancing multiple partnerships with pharmaceutical and biotech companies to develop therapies targeting cancer, fibrosis, obesity, and rare diseases. The company is headquartered in Seoul, South Korea. For more information, please visit AbTherx Media Contact Stacey Borders [email protected] SOURCE: AbTherx, Inc press release
Yahoo
13-05-2025
- Business
- Yahoo
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
AbTherx and Single Cell Technology incorporate ActivMAb® Technology into Atlas™ Mouse and AbTheneum™ antibody discovery platforms MOUNTAIN VIEW, CA / / May 13, 2025 / AbTherx, Inc., a biotechnology company with innovative transgenic technologies that simplify and accelerate antibody discovery, today announced a collaboration with Single Cell Technology and Vaccinex. AbTherx and Single Cell Technology will incorporate Vaccinex's ActivMAb® Technology into their respective workflows for complex drug targets. AbTherx's antibody discovery platform is built on two decades of experience and utilizes evolutionary intelligence to identify diverse and developable human antibody sequences. This collaboration harnesses AbTherx's suite of next-generation transgenic technologies to advance drug development. The Atlas Full Human Diversity Mouse, an updated industry standard, generates human antibodies with the affinities and diversity required for efficient and successful therapeutic development. The Atlas Binary Fixed Light Chain Mouse streamlines the engineering, development, and manufacturing of bispecific antibodies, optimizing the process for greater efficiency. Meanwhile, the Atlas Long CDR3 Mouse leverages a rare, naturally occurring phenomenon to simplify the targeting of complex transmembrane proteins, such as GPCRs and ion channels, enhancing the precision of antibody-based therapeutics. "GPCRs and ion channels are validated drug targets, but limited extracellular domain access, difficulty producing stable, functional antigens, and the lack of antibody technologies to access deep pockets, have made these challenging targets for antibody discovery," said Justin Mika, Chief Executive Officer of AbTherx. "This partnership is an exciting example of how AbTherx is developing a multifaceted approach to overcome these challenges." Single Cell Technology will apply its proprietary AbTheneum single B cell screening platform to mine differentiated antibodies from the Atlas Mice. AbTheneum captures comprehensive functional and sequence data from antibody-secreting cells in parallel, enabling rapid identification of rare, high-performing hits. "AbTheneum's high-resolution discovery approach is ideally suited to extract the full potential of AbTherx's advanced mouse platforms," said Chun-Nan Chen, Chief Executive Officer at Single Cell Technology. "We have over a decade of experience across a wide range of targets, and we're proud to contribute our expertise to this collaborative effort." Vaccinex's proprietary ActivMAb® Technology enables expression of functional, properly folded complex proteins such as GPCRs and ion channels on the relatively simple membrane of poxvirus, providing a source of antigen for various antibody discovery strategies. "We believe that our technology is a powerful component of antibody discovery strategies targeting complex membrane proteins," said Ernest Smith, General Manager, ActivMAb of Vaccinex. "These relationships underscore ActivMAb's unique ability to address previously hard-to-drug targets in a format ideally suited for antibody discovery." Under the terms of the agreement, each party has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. About AbTherx AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit About Single Cell Technology, Inc. Single Cell Technology is an antibody discovery R&D provider with a pioneering platform that can both accelerate the process and capture all available data. Its team expertly deploys the patented AbTheneum™ technology-which combines innovations in multiple fields to overcome discovery challenges and move campaigns ahead quickly and efficiently. Single Cell has been delivering value for ten years to pharmaceutical clients, tailoring each campaign to the target biology. Several antibodies discovered by Single Cell have entered clinical trials, validating the quality of antibodies identified using AbTheneum™ screening. Learn more at About ActivMAb and Vaccinex, Inc. ActivMAb is a proprietary fusion protein technology that enables direct incorporation of multi-pass membrane proteins into the membrane of two antigenically distinct poxviruses. The protein of interest is correctly folded and expressed in the cell-derived viral membrane and does not require any detergents or refolding before downstream use. Antigen expressing virus can be readily purified and used for antibody selection with any in vitro display platform such that alternating between the two strains eliminates filters out anti-viral antibodies. In addition, direct immunization with antigen virions produces strong anti-antigen responses in vivo, possibly due to adjuvant properties of the virus. Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents infiltration and activation of immune cells in tumors and triggers damaging inflammation in neurodegenerative diseases. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. We believe pepinemab has also given promising results as a monotherapy in the Phase 1b/2 SIGNAL-AD study in Alzheimer's Disease, and the Company has previously published promising Phase 2 data suggesting a slowing of cognitive decline in Huntington's disease. AbTherx Media Contact Stacey Bordersstacey@ Vaccinex Media Contact Elizabeth Evanseevans@ SOURCE: AbTherx, Inc View the original press release on ACCESS Newswire Sign in to access your portfolio
Associated Press
12-05-2025
- Business
- Associated Press
AbTherx and Spice Biotechnologies Announce Multi-Program Antibody Discovery Collaboration
Immuno-oncology pioneer partners with AbTherx to build the next generation of immunotherapy drugs MOUNTAIN VIEW, CA / ACCESS Newswire / May 12, 2025 / AbTherx, Inc., a biotechnology company with innovative transgenic technologies that enable and accelerate antibody discovery, today announced a multi-program antibody discovery partnership with Spice Biotechnologies. The partnership will leverage AbTherx's suite of innovative Atlas™ Mouse technologies to deliver antibodies against targets selected by Spice Bio. AbTherx's antibody discovery platform is built on two decades of experience and utilizes evolutionary intelligence to identify diverse and developable human antibody sequences. This collaboration leverages AbTherx's novel, patent-pending Atlas Full Human Diversity Mouse, an updated industry standard with a strong IP position that generates fully human antibodies with the affinity and diversity required for efficient, successful drug development. It also utilizes the Binary Fixed Light Chain Transgenic Mouse which enables native-like IgG bispecific antibodies that improve manufacturability and developability. Through these innovative technologies and a deeply collaborative partnering model, AbTherx uniquely enables startups to efficiently manage resources, timelines, and technical risk. Spice Bio was founded by Alan J. Korman, a globally recognized leader in immunology and cancer research. With over 30 years of experience in drug development, Dr. Korman has shaped groundbreaking advancements in the field, most recently serving as an executive at Vir Biotechnology and Bristol Myers Squibb. Dr Korman led the discovery of a revolutionary approach to cancer immune therapy and immune checkpoint blockade, which has driven the development and approval of several groundbreaking oncology drugs. Working with AbTherx cofounders at Medarex and BMS, Dr. Korman found incredible success discovering and developing the world's first immune checkpoint inhibitors, YERVOY® (ipilimumab) and OPDIVO® (nivolumab). 'Over the last 20 years, the Spice Bio team has had an incredible track record of creating successful life-saving drugs in partnership with some of our AbTherx cofounders. Because of this long, productive history, we are particularly excited to partner with Dr. Korman again in his new venture to create the next generation of immunotherapy drugs,' said Justin Mika, Chief Executive Officer of AbTherx. 'AbTherx is uniquely positioned to lead the next wave of antibody therapeutics with continuous innovation in antibody discovery technology, deep experience in antibody discovery, and startup-friendly partnering models.' From top 10 pharmaceutical companies to virtual startups, leading organizations in antibody therapeutics have rapidly adopted the AbTherx platform, resulting in over 50 initiated programs across over a dozen partners in the past nine months. Under the terms of the agreement, Spice Bio has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbTherx will receive research payments and is eligible to receive downstream clinical and commercial milestone payments, as well as royalties on net sales of products. About AbTherx AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit Media Contact Stacey Borders [email protected] SOURCE: AbTherx, Inc. press release
